Oncology blockbusters must target adjuvant settings to secure massive patient volumes.
Facing crowded markets and high clinical failure rates in metastatic cancers, drugmakers are shifting clinical development to post-surgical adjuvant settings with longer treatment windows and larger patient pools.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
To secure larger patient volumes and extend treatment windows, the drug is expanding from late-stage metastatic use into the post-surgical adjuvant setting.
Shifting the clinical focus of these blocking agents to early-stage adjuvant settings vastly expands candidate eligibility and treatment durations.
Roche strategically pivots its giredestrant candidate to the high-volume adjuvant market after failing its first-line metastatic trial.
Oncology blockbusters are combining targeted therapeutics to establish superior clinical benefit in the post-surgical adjuvant setting, maximizing early patient market volumes.